---
figid: PMC4859220__nihms-780239-f0004
figlink: /pmc/articles/PMC4859220/figure/F4/
number: F4
caption: Scientific rationales of potential therapeutic combinations with PD pathway
  blockade. Multiple layers of immunosuppressive mechanisms, weak T cell activation,
  tumor intrinsic biological pathways contribute to cancer progression and therapy
  resistance. The different combinations with PD pathway blockade may yield a synergistic
  or additive clinical response.
pmcid: PMC4859220
papertitle: 'PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms,
  Response Biomarkers and Combinations.'
reftext: Weiping Zou, et al. Sci Transl Med. ;8(328):328rv4-328rv4.
pmc_ranked_result_index: '3040'
pathway_score: 0.7319708
filename: nihms-780239-f0004.jpg
figtitle: Scientific rationales of potential therapeutic combinations with PD pathway
  blockade
year: ''
organisms: Homo sapiens
ndex: b6e77990-dea3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4859220__nihms-780239-f0004.html
  '@type': Dataset
  description: Scientific rationales of potential therapeutic combinations with PD
    pathway blockade. Multiple layers of immunosuppressive mechanisms, weak T cell
    activation, tumor intrinsic biological pathways contribute to cancer progression
    and therapy resistance. The different combinations with PD pathway blockade may
    yield a synergistic or additive clinical response.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL6
  - CXCL8
  - NT5E
  - ENTPD1
  - CXCL12
  - IL22
  - CD276
  - VEGFD
  - PGF
  - VEGFA
  - TNFRSF9
  - CD40LG
  - ERBB2
  - APC
  - TGFB1
  - TGFB2
  - LAG3
  - TNFRSF4
  - CCR4
  - TNFSF4
  - CD274
  - PDCD1
  - CD40
  - CTLA4
  - CXCR4
  - IDO1
  - IFNA1
  - HAVCR2
  - TNF
  - TGFB3
  - TIGIT
  - VTCN1
  - VEGFB
  - VEGFC
  - CARTPT
  - CCL22
genes:
- word: IL-6,
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: IL-8,
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: CD39/CD73
  symbol: CD73
  source: hgnc_alias_symbol
  hgnc_symbol: NT5E
  entrez: '4907'
- word: CD39/CD73
  symbol: CD39
  source: hgnc_prev_symbol
  hgnc_symbol: ENTPD1
  entrez: '953'
- word: Targetingangiogenesis:VEGF,CXCL12/CXCR4blocker
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: IL-22
  symbol: IL22
  source: hgnc_symbol
  hgnc_symbol: IL22
  entrez: '50616'
- word: B7-H3,
  symbol: B7-H3
  source: hgnc_alias_symbol
  hgnc_symbol: CD276
  entrez: '80381'
- word: VEGF,
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF,
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF,
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: Tcellactivation:CD40/CD40L,OX40/OX40L,41BB
  symbol: 4-1BB
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF9
  entrez: '3604'
- word: Tcellactivation:CD40/CD40L,OX40/OX40L,41BB
  symbol: CD40L
  source: hgnc_alias_symbol
  hgnc_symbol: CD40LG
  entrez: '959'
- word: 4-1BB
  symbol: 4-1BB
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF9
  entrez: '3604'
- word: Anti-HER2/neu
  symbol: NEU
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: TGFB,
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGFB,
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: LAG3,
  symbol: LAG3
  source: hgnc_symbol
  hgnc_symbol: LAG3
  entrez: '3902'
- word: OX40/OX40L,
  symbol: OX40
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF4
  entrez: '7293'
- word: CCR4/CCL22,
  symbol: CCR4
  source: hgnc_symbol
  hgnc_symbol: CCR4
  entrez: '1233'
- word: OX40/OX40L,
  symbol: OX-40L
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF4
  entrez: '7292'
- word: PD1/PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PD1/PD-L1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: CD40/CD40L,
  symbol: CD40
  source: hgnc_symbol
  hgnc_symbol: CD40
  entrez: '958'
- word: CTLA4,
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: CXCL12/CXCR4
  symbol: CXCR4
  source: hgnc_symbol
  hgnc_symbol: CXCR4
  entrez: '7852'
- word: IDO
  symbol: IDO
  source: hgnc_prev_symbol
  hgnc_symbol: IDO1
  entrez: '3620'
- word: IFN
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: TIM3,
  symbol: Tim-3
  source: hgnc_alias_symbol
  hgnc_symbol: HAVCR2
  entrez: '84868'
- word: TNF
  symbol: TNF
  source: hgnc_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: TGFB,
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: TIGIT
  symbol: TIGIT
  source: hgnc_symbol
  hgnc_symbol: TIGIT
  entrez: '201633'
- word: B7-H4,
  symbol: B7-H4
  source: hgnc_alias_symbol
  hgnc_symbol: VTCN1
  entrez: '79679'
- word: VEGF,
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF,
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: CAR-T,
  symbol: CART
  source: hgnc_alias_symbol
  hgnc_symbol: CARTPT
  entrez: '9607'
- word: CCR4/CCL22,
  symbol: CCL22
  source: hgnc_symbol
  hgnc_symbol: CCL22
  entrez: '6367'
chemicals: []
diseases: []
figid_alias: PMC4859220__F4
redirect_from: /figures/PMC4859220__F4
figtype: Figure
---
